- Actor, advocate and founder of The Michael J. Fox Foundation named a laureate of the 2026 Lasker Awards, widely recognized as America's preeminent research prize

- Fox honored "for empowering patients' voices and accelerating research to find improved therapies and a cure for Parkinson's disease"

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today celebrates founder Michael J. Fox as the recipient of the 2026 Lasker~Bloomberg Public Service Award, recognizing his extraordinary contributions to advancing Parkinson's research through scientific entrepreneurialism, courageous activism, community mobilization and philanthropic humanitarianism.

Widely recognized as America's preeminent biomedical research prize, the Lasker Awards are among the most prestigious honors in science and medicine — more than 100 Lasker Laureates have also received the Nobel Prize. The Lasker~Bloomberg Public Service Award honors individuals and organizations whose public service accelerates progress in medical science or health. The official Lasker citation recognizes Fox for "dispelling the stigma of the disease and spearheading a revolution in the world of Parkinson's research."

"Receiving a Lasker is humbling," said Michael J. Fox. "I share this honor with everyone who works side by side with us — scientists, policymakers, and most of all, the patients and families who give their all to this cause. I am deeply grateful to them, and to everyone who is part of the effort to end Parkinson's."

Diagnosed with Parkinson's in 1991 at age 29, Michael J. Fox founded MJFF in 2000 with an ambitious goal: accelerate the development of better Parkinson's treatments and, ultimately, a cure. At a time when Parkinson's research was characterized by chronic underinvestment and stalled innovation, Fox helped pioneer an entrepreneurial approach to biomedical philanthropy, assembling an in-house team of PhD-trained scientists and business strategists to learn from patients themselves about their unmet medical needs and fund high-risk, high-reward research that patients themselves would want pursued.

Under the leadership of Fox, CEO and Co-Founder Deborah W. Brooks and a skilled Foundation staff, MJFF has rapidly grown into the world's largest nonprofit funder of Parkinson's research, having funded more than $3 billion globally to date, a portion in partnership with the Aligning Science Across Parkinson's (ASAP) initiative funded by the Sergey Brin Family Foundation. Lasker and Nobel Laureate Randy Schekman, PhD, serves as ASAP's scientific advisory board chair and was Michael J. Fox's Lasker nominator.

In its short history, the Foundation has transformed the Parkinson's landscape, helping build the most robust therapeutic pipeline in the disease's history and cultivating a research ecosystem that has supported 23 new drug approvals over the past decade. Today, MJFF now invests significantly more in Parkinson's research each year than the U.S. federal government.

Fox has matched his commitment to scientific discovery with a powerful voice of advocacy. In 1999, before founding MJFF, he testified before Congress to call for greater federal investment in Parkinson's research. He later became a leading voice for research freedom, helping advance the national dialogue on stem cell research in the mid-2000s. The Foundation has carried that advocacy forward, most recently calling upon hundreds of thousands of grassroots policy advocates to help secure passage of the National Plan to End Parkinson's Act in July 2024, which established the National Parkinson's Project, the first comprehensive federal legislation dedicated to the disease.

Fox has been equally influential in ensuring that people living with Parkinson's have a seat at the table to inform research on the disease. His openness about his own experience helped smash stigma, while MJFF has created both formal and informal opportunities for patients and families to help shape the Foundation's scientific agenda. Under his leadership, the Foundation has built a global network of patients, academic researchers, clinicians, industry leaders and philanthropists united by a shared sense of urgency. Today, that community includes an audience of nearly four million including 1.2 million donors since inception — a testament to Fox's ability to transform individual acts of generosity and support into a global community.

The Lasker Award adds to a significant body of recognition for Fox's humanitarian leadership. For nearly three decades, he has transformed his Parkinson's diagnosis into a global call to action, using his public platform to champion research investment and scientific risk-taking while elevating the needs of patients and families. His many distinctions include the Presidential Medal of Freedom, the Academy of Motion Picture Arts and Sciences' Jean Hersholt Humanitarian Award, the Order of Canada, and multiple honorary degrees from leading universities and medical institutions worldwide. An acclaimed actor and bestselling author, Fox has brought Parkinson's into public view with candor, optimism and humor, inspiring millions around the world.

Since 1945, the Lasker Foundation has awarded more than 400 prizes through the Lasker Awards, recognizing the contributions of leaders who have made major advances in the understanding, diagnosis, treatment, cure, and prevention of human disease. The Awards carry an honorarium of $250,000 for each category. They will be presented at a gala ceremony in New York City on Thursday, September 17, 2026. The full list of Lasker Award recipients is available at laskerfoundation.org.

"Experts told Michael early on that Parkinson's science was 'ahead of the money.' He took that insight and went all in on a clear vision: put patients at the center and accelerate relevant, rigorous and collaborative science. His celebrity generated visibility, but his humanitarian spirit, business instincts, and tenacious optimism provided the blueprint for results," said Debi Brooks, MJFF's CEO and Co-Founder. "This honor affirms what the Parkinson's community has long seen in Michael — a champion who pushes science beyond the status quo and closer to solutions that improve patients' lives."

About The Michael J. Fox Foundation for Parkinson's Research (MJFF)

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors, and volunteers. In addition to funding $3 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, MJFF forges groundbreaking collaborations, creates robust open-access data sets and biosample libraries with its landmark clinical study (PPMI), increases the flow of participants into Parkinson's disease clinical trials with its online tool (Fox Trial Finder), promotes Parkinson's awareness, and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at www.michaeljfox.org, Facebook, Instagram and LinkedIn.

SOURCE The Michael J. Fox Foundation for Parkinson's Research

Share this article

SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, and breast cancer vaccine clinical trial patient, Sherie Steinberg, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, September 12, at 7:00 PM ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.

During the interview, Dr. Kumar will discuss recently announced successes in cancer vaccine development and Anixa's breast cancer vaccine that is expected to be used not only to treat cancer and to prevent recurrence, but also as a preventive vaccine to reduce the risk of ever developing breast cancer. In addition, Sherie Steinberg, a breast cancer survivor who participated in Anixa's Phase 1 clinical trial, will discuss her breast cancer journey and her experience receiving Anixa's vaccine.

You may view the segment on Bloomberg TV (for channel information, check your local listings) or on the internet at https://www.youtube.com/watch?v=jCUvJY2bjNU.

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:

Mike Catelani

President, COO & CFO

[email protected]

408-708-9808

SOURCE Anixa Biosciences, Inc.

Share this article

From the leader in longevity science, TELI brings together personalized, physician-led care, uncompromising quality and safety standards, and a commitment to advancing clinical research

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Elysium Health, Inc.™, the leading longevity science company, today announced the opening of The Elysium Longevity Institute™ (TELI), marking the company's most significant milestone since its launch in 2015 and establishing a new standard for personalized, physician-led longevity medicine. TELI reflects a growing consumer demand for a more rigorous approach to longevity care—one built on physician oversight, uncompromising quality and safety standards, and a commitment to advancing clinical research. Members can access personalized longevity protocols that integrate prescription therapies, supplements, peptides, and ongoing clinical care through a single, comprehensive program. Grounded in the scientific rigor that has defined Elysium for more than a decade, TELI is led by Chief Medical Officer Omar Baker, M.D., F.A.A.P., in collaboration with Elysium co-founder, Chief Scientist, and Novartis Professor of Biology at MIT Leonard Guarente, Ph.D.

Dr. Baker brings nearly 15 years of experience spanning clinical care, healthcare innovation, and executive leadership. Most recently, as Executive Vice President and Deputy Chief Medical Officer at UnitedHealth Group, the world's largest health care company, he helped shape clinical strategy and innovation at scale—experience that now informs Elysium's vision for the future of longevity medicine.

"Longevity medicine has reached an inflection point—scientific advances are arriving faster than ever before," said Dr. Baker. "These advances raise the standard for how they should be delivered. Responsible longevity medicine isn't defined by access to a particular therapy. It's defined by thoughtful clinical judgment, individualized care, and rigorous quality standards. People want to understand which interventions are appropriate for them, how those interventions work together, and how their care should evolve as their health changes. Pairing those principles with a commitment to generating new clinical evidence creates a model that can advance both patient care and the field itself. That's the philosophy behind The Elysium Longevity Institute. We believe it's the future of longevity medicine—and the standard every patient deserves."

The Elysium Longevity Institute provides a personalized, physician-led longevity program designed to optimize healthspan and lifespan through ongoing clinical care. Following a comprehensive medical intake, licensed providers develop individualized protocols tailored to each person's medical history, lifestyle factors, and health goals. With ongoing clinical care, protocols are adjusted according to the individual's response to treatment over time and as their health, lifestyle, or goals change. At launch, the program includes 18 longevity-focused protocols, including prescription medications, peptides, supplements, and vitamins in oral, intranasal, and injectable forms, with ongoing clinical support and personalized treatment adjustments throughout.

"For decades, the goal of aging research was to understand why we age," said Elysium Chief Scientist and Novartis Professor of Biology at MIT Leonard Guarente, Ph.D. "Today, we're entering a new era where many of those discoveries are beginning to translate into interventions that may actually help people live healthier, longer lives. The next challenge is ensuring those discoveries are translated responsibly into clinical practice while continuing to generate the evidence that moves the field forward. The Elysium Longevity Institute represents an important step toward making that vision a reality."

"When we launched Elysium in 2015, our mission was to bring the world's best aging research out of the lab and into people's lives," said Elysium co-founder and CEO Eric Marcotulli. "Over the past decade, we've helped define new categories in longevity, supported more than 20 clinical trials, and demonstrated that scientific rigor and commercial innovation can go hand in hand. Our responsibility isn't simply to make the latest advances in longevity science available—it's to evaluate them rigorously, deliver them responsibly, and continue contributing to the evidence that shapes the future of longevity medicine. That's the standard we've worked to uphold for more than a decade, and it's the standard that will define the Institute."

The Elysium Longevity Institute is open to eligible patients in the United States. Individuals can learn more, complete a comprehensive medical intake, and begin personalized, physician-led longevity care at elysiumhealthrx.com. While TELI launches with 18 longevity-focused protocols, Elysium will continue expanding its clinical offerings as the science advances and new therapies become available. Consistent with the company's longstanding commitment to science, uncompromising quality and safety standards, and advancing clinical evidence, every new protocol will be evaluated with the same rigor that Elysium has applied since 2015.

About Elysium Health™

Elysium Health's™ mission is to solve the biggest challenges in health with science, to help people lead healthier lives. Working directly with the world's leading scientists and clinicians, Elysium Health™ is committed to translating critical advancements in aging research into health solutions people can access today. Elysium Health™ is backed by General Catalyst, Morningside Ventures, Breyer Capital, Mayo Clinic Ventures, and other notable investors. Learn more at elysiumhealth.com.

SOURCE Elysium Health

Share this article

National Franchise T.A.C.T. Celebrates Franchisee Feature in Esquire Magazine Highlighting Industry Excellence

ST. LOUIS, Sept. 9, 2026 /PRNewswire/ -- T.A.C.T. (Trauma and Casualty Team), a leading nationwide franchise specializing in biohazard remediation and trauma cleanup, proudly announces that franchise owner David Lesaffre was recently featured in an in-depth profile by Esquire magazine. The article showcases the vital role T.A.C.T. franchise owners play as "The Last Responders" in local communities.

The article, titled "The Trauma Cleaners," examines the growing demand for professional biohazard and hoarding remediation, following Lesaffre's journey as he built successful franchise locations including T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth.

"When I met David and Leanne, I knew they had the compassion and drive to run their business the right way," said Matt Lovasz, Founder and CEO of T.A.C.T. "They came to St. Louis, went through the training, and then went home and did the jobs most people won't touch. Esquire spent real time with them and wrote a realistic view of what it takes to build a T.A.C.T. Franchise. That is what I'm proud of."

Founded by former law enforcement officer Matt Lovasz, T.A.C.T. provides comprehensive training, proprietary cleaning protocols, and ongoing business support to help franchise partners build successful, recession-resistant businesses in the multi-billion-dollar remediation market.

The Esquire feature details how T.A.C.T. franchisees navigate high-stakes scenarios—including biohazard recovery, vehicle decontamination, and large-scale hoarding management—while maintaining strict industry protocols and discreet client service.

"As our brand continues to expand nationwide, features like this demonstrate the strength and purpose of the T.A.C.T. business model," added Lovasz. "David and Leanne's success in Arizona and Texas shows how passionate and caring franchise owners can build thriving, multi-unit businesses that perform an indispensable public service."

T.A.C.T. currently operates franchise territories across the United States, offering 24/7 biohazard, crime scene, mold, and hoarding cleanup services.

To read the full article or learn more about T.A.C.T. franchise opportunities, visit https://tactthelastresponders.com/.

About T.A.C.T. (Trauma and Casualty Team)

Founded by former law enforcement professionals, T.A.C.T. is a premier nationwide biohazard remediation franchise network. Known as "The Last Responders," T.A.C.T. delivers expert, compassionate remediation services for trauma, biohazards, hoarding, infectious diseases, and crime scenes to residential and commercial clients nationwide.

Media Contact:

Matthew Lovasz

314-603-0191

[email protected]

https://tactthelastresponders.com/

SOURCE T.A.C.T.

Share this article

Registration Opens for The 2027 NAMM Show -- the Music Industry's Can't-Miss, Must-Attend Global Gathering

Five days. 60,000+ industry professionals. 122 countries. $9.8 billion in buying power. 70 million social views. One place where the global music industry comes together to shape what's next.

CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- NAMM (The National Association of Music Merchants), the world's largest not-for-profit music trade organization, today announced that registration ( is now open for The 2027 NAMM Show, taking place January 26–30, 2027, at the Anaheim Convention Center in Anaheim, Calif. Register for The 2027 NAMM Show: https://www.namm.org/thenammshow/registration-process

For five days, the global music industry will converge in Anaheim for the most consequential week on the music products calendar — bringing together the people, products, ideas and experiences shaping the future of music and live entertainment. The 2027 NAMM Show will unite manufacturers, retailers, distributors, artists, creators, technology professionals, educators, media, influencers and industry leaders for business, product discovery, professional development, live music, networking and celebration.

The main exhibition floors open January 28–30 for three days of immersive brand experiences, product launches, hands-on demonstrations, business meetings, creator engagement and discovery across the global music products landscape. The experience begins two days earlier, with education, professional development, networking, special events and industry gatherings beginning Tuesday, January 26.

Following three years of transformation — and building on the momentum of NAMM's milestone 125th anniversary celebration in 2026 — The 2027 NAMM Show is bigger in ambition and broader in reach than ever before. It is no longer simply a trade show. It is the global platform where commerce, content, education, innovation, creator culture, professional development and industry celebration converge.

"The NAMM Show has evolved into a global platform that brings together the people, products and ideas shaping the future of music," said John Mlynczak, NAMM president and CEO. "The 2027 show builds on that momentum with more opportunities to do business, experience incredible brands throughout the show and the diversity of our industry, connect with live musical performances and content creators, plus celebrate the achievements of our global industry throughout the entire week."

For brands, retailers and professionals, The NAMM Show is where business gets done, relationships are built and the next opportunities emerge. But the audience is no longer limited to buyers and sellers.

The 2027 program expands that opportunity with new summits and experiences designed for the full breadth of the global music community — from entrepreneurs and executives to retailers, artists, educators, engineers, creators and technology professionals.

Across the NAMM campus, attendees will experience performances and appearances from emerging artists, creators, celebrated performers and industry icons, celebrating the music, technologies, products and people that make the entire ecosystem possible.

The past three NAMM Shows have featured artists and groups including Jon Batiste, Jacob Collier, Queen Cora, Billy Corgan, Green Day, Primus, Charlie Puth, Chad Smith, Lindsey Stirling, Jack White and Victor Wooten.

The music industry is changing faster than ever. New technologies are transforming how music is created. Creators are reshaping how products are discovered. Global markets are opening new opportunities. And the boundaries between music, technology, entertainment and content continue to disappear.

Members and qualified industry professionals are encouraged to register now and begin planning their experience for the global music industry's can't-miss week in Anaheim.

Register for The 2027 NAMM Show: https://www.namm.org/thenammshow/registration-process

For information about The 2027 NAMM Show and the Show's digital brand experience please visit https://exhibit.namm.org/

For more information about The 2027 NAMM Show: https://www.namm.org/thenammshow/attend

Media Contact:

Josh Vittek

760-505-5674

SOURCE NAMM

Share this article

KANSAS CITY, Mo., Sept. 9, 2026 /PRNewswire/ -- Caravel Autism Health, a leader in the diagnosis and treatment of young children on the autism spectrum, is hosting a ribbon-cutting on Thursday, September 10 to celebrate the grand opening of a new, state-of-the-art autism therapy clinic. The clinic, located at 11140 Locust Street in Kansas City, MO, is staffed by childhood autism experts who specialize in Applied Behavior Analysis therapy.

Using positive reinforcement, ABA therapy helps children with autism build skills – from communication to social interaction – and prepare to succeed in a school environment. The effectiveness of ABA therapy is recognized by the American Academy of Pediatrics and the Centers for Disease Control and Prevention.

The clinic features colorful, sensory-friendly spaces where children work one-on-one with therapists to improve essential skills, develop confidence, and learn to connect with the world around them. Caravel offers a full range of services including diagnostic evaluation, ABA therapy, and family support and counseling.

"At Caravel, our mission is to change lives," said CEO Mike Miller. "We do so by investing in communities like Kansas City to bring best-in-class resources and services to families. These new clinics ensure that children with autism have access to the customized therapy that will help them reach their greatest potential."

One in 31 children is on the autism spectrum, according to the CDC's latest estimate. "As clinicians who specialize in working with children with autism, we understand how important it is to provide access to services in the early developmental years when we can deliver the greatest impact," explained Caravel's Kansas City Clinic Director Megan Belew, M.Ed., BCBA, LBA. "We're excited to expand our footprint within the Kansas City South area so that more local families can access the diagnostic and therapeutic services they need."

For more information about autism services for children or employment opportunities with Caravel, call 816-927-2360 or visit caravelautism.com.

About Caravel Autism Health

Since 2009, Caravel Autism Health has been committed to helping families navigate the challenges of autism and providing leadership that creates better outcomes. Our team of clinical experts specializes in evaluation, diagnosis, and therapy for young children on the autism spectrum. Caravel's research-based and data-driven programs are designed to provide better outcomes that help children with autism reshape their development and embrace new ways of interacting with the world.

SOURCE Caravel Autism Health

Share this article

LOS ANGELES, Calif., Sept. 9, 2026 /PRNewswire/ -- Vision Films announces the worldwide Transactional VOD release of Isolation on September 22, 2026, through a deal with Legacy Distribution. The intense drama was directed and produced by James Drake Coleman and co-produced by Joe Barajas of Regardless Productions. Isolation was filmed in various locations across Texas starting in Austin that crisscrossing the state from Monahans Sandhills State Park in West Texas to the Pineywoods forest region of East Texas.

Originally an award-winning 16-minute short film, this passion project of Coleman's became a full-length feature made possible by angel investors. Coleman, who also stars in, edited and scored the film, credits the support of friends for making his cinematic dream come true.

The dystopian adventure follows Logan, a prisoner aboard a desolate spacecraft, as he undertakes dangerous missions to retrieve alien artifacts in exchange for a chance at freedom. His only companion is the ship's onboard messaging interface, "AMI." As Logan faces isolation and danger, the film explores questions of purpose, survival, and the nature of his own mind. Watch the trailer: HERE

Lise Romanoff, CEO and Managing Director of Vision Films says, "You will never quite know what is real or a trick of the isolated and paranoid mind of this space prisoner. Isolation will keep you riveted and guessing until very last scene."

Filmmaker James Drake Coleman shares, "I feel so blessed to have been able to make this film with such extraordinary people. Though our crew was extremely small, we packed a punch. I wanted to make this film with the psychology of isolation always at the forefront and to draw the audience into that space, even in the quietest moments. Everything was deliberate and I made the film I saw in my head. I couldn't have done it without the support and love from everyone who helped create it."

Isolation stars James Drake Coleman (Divorce Tears from the Alpha, But I Shine Alone), the voice talent of singer, actress, producer and flutist Sheilava (Callbacks), Timothy Banfield (The REAL Thunderbolts Story), Erv Brown (Armstrong: Dark Secrets), Chiara McCarty (LBJ: Triumph and Tragedy).

Available on streaming platforms including Amazon, Apple TV/iTunes, GooglePlay and most cable platforms across the US, Canada, and UK on September 22, 2026. For more and the most up to date information, visit www.isolationuniverse.com.

About Vision Films

Vision Films is a leading independent sales and VOD aggregator specializing in the licensing, marketing, and distribution of over 800 feature films, documentaries, and series from some of the most prolific independent film producers in the world. Led by Lise Romanoff, Managing Director/CEO Worldwide Distribution, Vision Films releases 2-4 films a month across Theatrical, VOD, DVD, and television platforms. visionfilms.net

About Legacy Distribution

Legacy Distribution is a leading Worldwide Content Distributor reaching the fast-growing global audience across all viewing platforms. Legacy Distribution brings deep expertise in U.S. and International Program Distribution, Digital Media Distribution, Content Acquisition, Corporate Development, and Strategic Planning. Legacy represents thousands of hours of programming including off-network Dramas, Documentary Specials, Music, Lifestyle, Children's Educational programming, and Features of all genres. Legacy Distribution is proud to work with reputable global Broadcast, Cable, and Digital partners worldwide and is at the forefront of constantly seeking innovative ways to maximize the value of client's content through innovative channels of distribution. legacydistribution.com

Contact:

Andrea McKinnon

8184159442

SOURCE Vision Films, Inc.

Share this article

First Franchisee in Brand History Recognized for Leadership, Business Performance, and Role in Shaping the System's Future

RICHARDSON, Texas, Sept. 9, 2026 /PRNewswire/ -- Service Experts, one of the nation's leading residential HVAC service companies, announced today that Trey Thomas-Piazza, the company's first-ever franchisee, has been named a 2026 Franchisee of the Year by the International Franchise Association (IFA). The prestigious recognition comes as Thomas-Piazza continues to lead the Tulsa market while playing a broader role in helping shape the future of Service Experts' franchise system.

Thomas-Piazza's path to franchise ownership is closely tied to the evolution of Service Experts itself. After spending years with the company in leadership roles spanning maintenance, installation, and operations, Thomas-Piazza ultimately became General Manager of the Tulsa market. When Service Experts launched its franchise program in 2025 after more than three decades as a primarily corporate-owned business, he saw an opportunity to take a market he knew inside and out and invest in its future as a franchise owner.

As the company's first franchisee, Thomas-Piazza became the first to put the Service Experts franchise model into practice. His transition from corporate leader to franchise owner provided Service Experts with an early opportunity to test, refine, and strengthen its franchise infrastructure while maintaining continuity for employees, customers, and vendor partners.

"Trey helped show us what this model could look like in action," said Nick Ridgway, Vice President of Franchise Development for Service Experts. "He understood the business, the people, and the systems better than almost anyone, and he took a tremendous amount of personal and professional trust in making that transition. What he has done since then has helped set the standard for the franchisees who have followed."

The IFA's Franchisee of the Year awards recognize franchise owners who demonstrate excellence in business, contribute to their communities, create opportunities for others and support their fellow franchisees. Nominated by their franchise brands, recipients represent IFA member companies across industries and communities throughout the country. Thomas-Piazza will be recognized at the IFA26 Advocacy Summit in Washington, D.C., Sept. 14-16.

"Franchisees of the Year demonstrate what franchising is all about – individuals who have committed their lives and careers to the betterment of those around them, building something bigger than themselves," said Matt Haller, President and CEO of the International Franchise Association. "Through their leadership, they create jobs and build careers, give back to their communities, and support other franchisees, all while exemplifying the entrepreneurial spirit at the heart of franchising. We are proud to recognize Trey with IFA's highest honor for individual franchisees and celebrate his commitment to making a difference both within his business and beyond."

Thomas-Piazza's recognition comes at an important point in Service Experts' franchise expansion. Within its first year of franchising, the company has expanded to five franchisees with 16 territories across the network, bringing its decades of operational experience, established brand infrastructure, and national resources to entrepreneurs looking to build businesses in the essential residential HVAC industry.

Service Experts continues to seek qualified entrepreneurs interested in building businesses within the residential HVAC industry with the support of an established national platform. To learn more about franchising opportunities with Service Experts, visit www.serviceexperts.com/franchising.

ABOUT SERVICE EXPERTS:

Founded in 1996 and headquartered in Richardson, Texas, Service Experts is one of the largest residential HVAC service providers in the United States. The company operates a nationwide network of locally operated service centers delivering heating, cooling, plumbing and electrical solutions. For nearly three decades, Service Experts has combined deep local expertise with the scale and resources of a national organization to provide proactive, reliable home system care proven by its average rating of 4.9 out of five stars on Google across hundreds of thousands of reviews. Learn more at ServiceExperts.com or follow Service Experts on Facebook and LinkedIn.

SOURCE Service Experts LLC

Share this article

Protein Pints Expands Protein Pops Into Target and Kroger After Sold-Out Summer Debut

High-Protein Ice Cream Bars Land at Two Major National Retailers After Selling Through Initial Online Inventory in One Day

GRAND RAPIDS, Mich., Sept. 9, 2026 /PRNewswire/ -- Following a breakout summer debut, Protein Pints, the fast-growing high-protein ice cream brand, is bringing Protein Pops to Target and all of Kroger's Family of Stores this month. The brand's high-protein ice cream bars are rolling out at Target this week, with Kroger following September 13.

Protein Pops debuted in June as Protein Pints' first major expansion beyond pints, bringing the brand's protein-forward approach to ice cream into a convenient, individually portioned format with 10g of protein per pop. The launch saw immediate consumer interest, with initial online inventory selling through in less than eight hours, exceeding online projections by more than 10X. The bars have since continued to build momentum at Sprouts Farmers Market stores throughout the summer.

"From the response we saw within the first few hours of launch, it was clear consumers were excited to get everything they love about Protein Pints in a convenient new format," said Paul Reiss, co-founder and CEO of Protein Pints. "Bringing Protein Pops to Target and all Kroger Divisions means significantly more people can now find them during their everyday grocery run, and it's an exciting next step as we continue offering people more frozen options to enjoy eating their protein".

Available in Caramel Crunch, Vanilla Crunch, Peanut Butter Crunch and Mint Crunch, Protein Pops feature creamy, high-protein ice cream dipped in a rich, crispy, quinoa-studded milk chocolate coating. Each bar delivers 10 grams of complete protein, 180–190 calories and at least 75% less sugar than traditional ice cream, with no artificial sweeteners. The bars are made with natural ingredients, are gluten-free and contain all nine essential amino acids.

The expanding footprint of Protein Pops marks a new chapter for this fast-growing line extension, increasing availability to more than 4,000 retail locations nationwide by mid-September. Designed for everyday enjoyment, from an afternoon snack to post-workout fuel or an evening treat, Protein Pops open the brand to new occasions while delivering the same balance of protein and indulgence that has fueled Protein Pints' rapid rise.

Protein Pops are now available nationwide at Target and Sprouts Farmers Market, with Kroger's Family of Stores availability beginning September 13.

For more information, visit ProteinPints.com or follow @ProteinPints on social media.

About Protein Pints:

Protein Pints is a rapidly growing brand of protein ice cream, founded by two childhood friends during their recent college years, on a mission to help people enjoy their protein in one of America's favorite treats. With a focus on natural ingredients and innovative recipes, Protein Pints is redefining what it means to enjoy functional ice cream, offering a guilt-free indulgence that tastes amazing and supports consumers' nutritional goals. Protein Pints products are packed with 30 grams of protein per pint, made with only natural ingredients, lower sugar, zero artificial sweeteners and gluten-free. In 2026, Protein Pints expanded beyond the pint with the launch of Protein Pops, bringing its signature approach to protein-packed indulgence into a convenient grab-and-go format with 10 grams of protein per bar.

Media Contact

Sandy Blumberg

8582821095

[email protected] 

SOURCE Protein Pints

Share this article

Viral British Haircare Brand Hair Syrup Makes U.S. Retail Debut. Joins Target Beauty Studio, Bringing Hair and Scalp Care Solutions to Target Guests Nationwide

LOS ANGELES, Sept. 9, 2026 /PRNewswire/ -- Hair Syrup, the independently owned British haircare brand behind a viral range of pre-wash oil treatments, is officially entering the U.S. market with a nationwide launch at Target.

Beginning September 10, Hair Syrup will be available in more than 600 Target stores across the U.S. and on Target.com, marking a major milestone for a brand that has grown from a university kitchen-table project into a multimillion business without outside investment.

Founded in 2020 by Lucie Macleod while she was a university student experimenting with natural oils to help repair her own bleach-damaged hair, Hair Syrup has built its growth largely through social media, community and word of mouth.

The brand gained further attention following Macleod's appearance on BBC's Dragons' Den in January 2025, when all six investors declined to invest. Rather than slowing the business down, the appearance became a viral moment of its own. Hair Syrup has since grown its community and has ranked among the top five haircare brands globally on TikTok over the past 12 months.

Hair Syrup's expansion into the U.S. follows significant organic demand from American consumers. The brand's website currently receives more than 19,000 visits per day from the U.S. alone, despite Hair Syrup previously having no dedicated brick-and-mortar retail presence in the market.

That existing consumer demand, driven largely by viral content, recommendations and social discovery, made the U.S. a natural next market for the brand.

Hair Syrup will launch through Target Beauty Studio, Target's curated assortment of prestige, emerging and global beauty brands.

The assortment will include a selection of Hair Syrup's bestselling pre-wash and leave-in hair oils, including Rapunzel, its scalp circulation-focused blend, and Growsmary, developed to support scalp health.

"Entering the U.S. has always been part of our long-term vision for Hair Syrup, so to reach this point independently and without outside investors makes it incredibly special. We've seen amazing demand from American customers for years through our website and social community, and this feels like a very natural next step for the brand.

"The U.S. customer already knows Hair Syrup and has been asking for greater access to our products. Target has been such an incredible partner in launching the brand, and we are so excited to have them retailing the range through Target Beauty Studio Nationwide. Now our focus is making it easier for all customers to discover and shop the brand in a way that feels accessible, exciting and true to the community we've built." Lucie Macleod, Founder and CEO, Hair Syrup

The Target launch is the latest step in Hair Syrup's broader international growth. In the U.K., the brand has established a significant retail presence across major beauty and fashion retailers. The company will now focus on building its U.S. retail footprint while continuing to grow the digital and social community that first created demand for the brand among American consumers.

Contact:

Shaun Taylor

3107299945

SOURCE Hair Syrup

Share this article